Prognostic Value of Systemic Inflammatory Markers in Patients with Endometrioid-Type Endometrial Cancer: A Retrospective Analysis

Background Systemic inflammatory markers have emerged as prognostic indicators in various malignancies. This study investigates the relationship between preoperative inflammatory markers and survival outcomes in patients with endometrioid-type endometrial cancer. Methods This retrospective study analyzed 142 patients with endometrioid-type endometrial cancer who underwent surgical treatment between 2018 and 2024. Patients with coexistent adenomyosis and myoma uteri were excluded to eliminate confounding inflammatory effects. Preoperative inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), pan-immune-inflammation value (PIV), and other hematological parameters were analyzed. Results The median follow-up period was 28.0 months (range: 1–51 months, IQR: 16–37 months). Overall survival rate was 44.344 ± 1.278 months. Cumulative survival rates were 96% at 12 months, 88% at 24 months, 82% at 36 months, and 72% at 48 months. Several inflammatory markers showed significant prognostic value: DNI ≥ 0.005763 (HR: 2.485, 95% CI: 1.011–5.644), SIRI ≥ 2.059 (HR: 2.485, 95% CI: 1.042–5.923), and GLR ≥ 58.88 (HR: 2.841, 95% CI: 1.206–6.693). Conclusions Preoperative inflammatory markers, particularly SIRI and GLR, demonstrate significant prognostic value in endometrioid-type endometrial cancer. These readily available biomarkers may enhance risk stratification and guide personalized treatment strategies.